Merck & Co. Stock News

One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that could help the company overcome its challenges.

Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance and diversified revenue streams, supports strong profitability and mitigates concentration risk. MRK's proven investment track record and consistent dividend growth further reinforce its appeal as a...

Merck (MRK)'s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings exceeding expectations, the FDA's approval of Keytruda's new formulation, and an excellent upgrade from Wells Fargo, several factors contributed to this boost—let's delve into the main reasons for the r...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2025 Global Healthcare Conference.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference.

Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90.

The shortened holiday week is here, and the futures are trading higher this morning.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company's ongoing commitment to ad...